Abstract Targeting angiogenesis has become an established therapeutic approach to fighting solid tumor growth in cancer patients. Even though increased angiogenesis has long been recognized in various types of hematologic malignancies, the molecular basis underlying this angiogenic switch in leukemias remains poorly understood. The BM stroma is gaining increasing attention for its role in promoting leukemia growth and resistance against current treatments with tyrosine kinase inhibitors. This article provides a brief overview of the role of angiogenesis in leukemias, discusses recent insights into the role of placenta growth factor (PlGF), a VEGF family member, as a novel disease candidate in chronic myeloid leukemia (CML), and highlights the therapeutic potential of PlGF blockade for imatinib-resistant CML.
Sonja Loges, Thomas Schmidt, Maria Kleppe, Kim De Keersmaecker, Marc Tjwa, Christa Maes, Christiane Dewolf-Peeters, Geert Carmeliet, Jan Cools, Jean–Marie Stassen, Peter Carmeliet
Sonja Loges, Thomas Schmidt, Christa Maes, Bart Jonckx, Maria Kleppe, Kim De Keersmaecker, Marc Tjwa, Thomas Schenk, Karolien Beel, Christiane Dewolf-Peeters, Geert Carmeliet, Jan Cools, Richard E. Clark, Peter Vandenberghe, Tim H. Brümmendorf, Tessa L. Holyoake, Andreas Hochhaus, Peter Carmeliet
Himadri Roy, Shalini Bhardwaj, Mohan Babu, Suvi Jauhiainen, Karl‐Heinz Herzig, Anna Rita Bellu, Hidde J. Haisma, Peter Carmeliet, Kari Alitalo, Seppo Ylä‐Herttuala
Isabel Ben‐Batalla, Robert Erdmann, Heather G. Jørgensen, Rebecca Mitchell, Thomas Ernst, Gunhild von Amsberg, Philippe Schafhausen, Janna L. Velthaus, Stephen Rankin, Richard E. Clark, Steffen Koschmieder, Alexander Schultze, Subir K. Mitra, Peter Vandenberghe, Tim H. Brümmendorf, Peter Carmeliet, Andreas Hochhaus, Klaus Pantel, Carsten Bokemeyer, G. Vignir Helgason, Tessa L. Holyoake, Sonja Loges
Discussion(0)
No comments yet. Be the first to comment.